25Aug
Johnson & Johnson Announces Acquisition of Momenta For $6.5 Billion
Johnson and Johnson announced that it has entered into an agreement to acquire Momenta Pharmaceuticals, Inc. for $6.5 billion. The acquisition gives J&J’s Janssen unit full global rights to Momenta’s nipocalimab (M281), an anti-FcRn antibody designed to treat a number of autoantibody-driven disorders, including generalized myasthenia gravis (gMG), warm autoimmune hemolytic anemia (wAIHA), and hemolytic disease of the fetus and newborn (HDFN)....
By:
Goodwin
Related
With the number, type, and scope of paid leave laws constantly expanding, employers may struggle to ...
Read More >
Congress recently passed the economic stimulus package referred to as the Coronavirus Aid, Relief, a...
Read More >
Representative Jim Banks introduced a bill on 5 May 2020 to “place temporary restrictions on acquis...
Read More >
In a straightforward case, but one with widespread applicability today, the 9th Circuit Court of App...
Read More >
Today our employer focused legislative update zeroes in on “no rehire” provisions in settlement ag...
Read More >
After a false start three years ago, the federal Department of Labor (“DOL”) will finally be rolli...
Read More >